Increasing use of new treatments for kidney diseases boosts the market growth

Market Research Future (MRFR) has published a cooked research report on the “Chronic Kidney Disease Market” that contains information from 2018 to 2030. The Chronic Kidney Disease Market is estimated to register a CAGR of 5.40% during the forecast period of 2023 to 2030.

Market Highlights

The global Chronic Kidney Disease Market is accounted to register a CAGR of 5.40% during the forecast period and is estimated to reach USD 100.34 billion by 2030.

Chronic kidney disease refers to the long-term damage to the kidneys, leading to their gradual loss of function over time. It is a global health concern that affects millions of people worldwide and can lead to end-stage renal disease (ESRD) if not managed properly. The global chronic kidney disease market includes various segments, such as diagnostic tests, pharmaceuticals, and dialysis equipment.

Segment Analysis

The global Chronic Kidney Disease Market has been segmented based Diagnosis, Treatment, End User

The chronic kidney disease market segmentation, based on diagnosis, includes blood test, urine test, imaging test, and kidney biopsy. The blood tests segment is to hold the majority share in 2022 in the chronic kidney disease market revenue. This is due to rising burden of chronic kidney disease and expanding technologically advanced diagnostic products. In addition, the major test for the diagnosis of renal disease combines a blood test and aids in determining how well the kidneys are functioning. The blood test measures blood amounts of a secondary effect known as creatinine.

The chronic kidney disease market segmentation, based on Treatment, includes drugs, dialysis, and kidney transplant. The drugs segment is to hold the majority share in 2022 in the chronic kidney disease market revenue. This is due to increased government support for research and development, and the availability of funding for research contributions. Furthermore, A growing focus on the development of new drugs increased government support for research and development, and the availability of funding for research contributions.

The chronic kidney disease market segmentation is based on end-user that includes hospital & clinics and diagnostic centers. The hospital & clinics segment has dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. This is due to the availability of advanced technological devices and the increase in diabetes and chronic kidney disease decreases, the increasing number weekly dialysis in the hospitals and clinics, together with the development of wellness trends, particularly in developed countries.

Explore In-depth Details: Chronic Kidney Disease Market Research Report

Key Players:

MRFR recognizes the following companies as the key players in the global Chronic Kidney Disease Market — Abbott (US), Siemens (Germany), Beckman Coulter (US), F. Hoffmann-La Roche Ltd (Switzerland), ACON Laboratories, Inc (US), Nova Biomedical (US), ARKRAY (Japan), AstraZeneca (UK), GlaxoSmithKline Plc (UK), and Bayer AG (Germany)

Regional Analysis

The global Chronic Kidney Disease Market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. The North America chronic kidney disease market is expected to be the fastest growing during the study period. This is attributed to the rising prevalence of chronic kidney diseases, the presence of well-established healthcare infrastructure along with high health spending, and technologically advanced diagnostic tests in the region.

Europe chronic kidney disease market is expected to account for the second-largest market share due to the increasing incidences of chronic kidney diseases and growth in government expenditure in the healthcare sector in the region. Further, the Germany chronic kidney disease market is expected to hold 3rd place for the market share, and the UK chronic kidney disease market is expected to fastest-growing market, and which is in the 4th place in the European region. Furthermore, France chronic kidney disease market will hold the 5th place for the market share.

The Asia-Pacific chronic kidney disease market is expected to grow at a CAGR of XX% from 2022 to 2030. This is due to the due to the increasing incidences of end-stage diseases and high development in government expenditure in the healthcare industry in the Asia-Pacific region. Moreover, India chronic kidney disease market is expected to hold the largest market share, and China chronic kidney disease market is expected fastest-growing market in the Asia-Pacific region.

The Rest of the World includes the Middle East, Africa, and Latin America. This segment is projected to hold the least share in the chronic kidney disease market. In this region, the Middle East is anticipated to dominate owing to the as rising prevalence of diabetes resulting in renal diseases and rising incidences of renal diseases in the region. Furthermore, growing funding and participation from the public and private sectors in R&D initiatives, as well as advancements in the infrastructure of the area, encourage market growth.

Key Findings of the Study

• The global Chronic Kidney Disease Market is expected to reach USD 100.34 billion by 2030, at a CAGR of 5.40% during the forecast period.


• The North America chronic kidney disease market is expected to be the fastest growing during the study period


• The chronic kidney disease market segmentation, based on diagnosis, includes blood test, urine test, imaging test, and kidney biopsy.


• Abbott (US), Siemens (Germany), Beckman Coulter (US), F. Hoffmann-La Roche Ltd (Switzerland), ACON Laboratories, Inc (US), Nova Biomedical (US), ARKRAY (Japan), AstraZeneca (UK), GlaxoSmithKline Plc (UK), and Bayer AG (Germany)